Charles River Partners with Gazi University on Rare Disease Gene Therapy
Event summary
- Charles River Laboratories collaborates with Gazi University to provide plasmid DNA for AAV production and in vitro efficacy studies.
- Focus on Hyperphosphatemic tumoral calcinosis (HTC), a rare genetic disorder causing painful calcium deposits.
- Charles River will supply off-the-shelf research-grade AAV plasmids, accelerating early-stage gene therapy programs.
- Gazi University identified GALNT3 as the gene responsible for HTC.
- Collaboration aims to transform ground-breaking concepts into real-world therapies.
The big picture
This collaboration underscores the growing trend of academic institutions partnering with CDMOs to accelerate gene therapy development. Charles River's expertise in plasmid DNA production aligns with the increasing demand for advanced therapies targeting rare diseases. The deal highlights the strategic importance of integrating academic innovation with commercial-scale manufacturing capabilities.
What we're watching
- Execution Risk
- Whether Charles River can sustain the pace of innovation in gene therapy collaborations.
- Market Expansion
- How this partnership will affect Charles River's position in the rare disease gene therapy market.
- Regulatory Dynamics
- The pace at which regulatory approvals for gene therapies will impact future collaborations.
Related topics